<DOC>
	<DOCNO>NCT00323739</DOCNO>
	<brief_summary>This phase II trial evaluate combination bevacizumab + RAD001 patient metastatic renal cell carcinoma . In trial investigator evaluate combination patient previously untreated anti-angiogenesis agent patient previously receive one prior regimen contain anti-angiogenesis agent .</brief_summary>
	<brief_title>Bevacizumab ( Avastin ) RAD001 ( Everolimus ) Treatment Advanced Clear Cell Renal Carcinoma</brief_title>
	<detailed_description>All eligible patient receive : - Bevacizumab 10mg/kg , IV infusion , every 2 week - RAD001 10 mg mouth daily All patient evaluate response complete two course ( 8 week ) treatment . Patients objective tumor response stable disease continue treatment bevacizumab adn RAD001 schedule . Treatment continue disease progression occur .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Histologically document metastatic unresectable locally recurrent clear cell renal carcinoma . In patient mixed histology , clear cell component must comprise â‰¥ 75 % cancer Previous nephrectomy require following exception : Primary tumor &lt; 5cm Extensive liver ( &gt; 30 % liver parenchyma ) Multiple ( &gt; 5 ) bone metastasis , make nephrectomy clinically contraindicated procedure Patients may maximum 1 previous systemic regimen metastatic disease Patients may receive previous bevacizumab . However , patient receive agent antiangiogenic activity ( eg . sorafenib , SU11248 , AG013736 , PTK787 , thalidomide ) part firstline treatment eligible Patients may receive previous treatment mTOR inhibitor . ECOG performance status 0 1 Measurable disease Adequate liver , kidney bone marrow function No previous systemic treatment radiation therapy least 2 week prior study entry Patients must able understand nature study give write informed consent Age &lt; 18 year Treatment &gt; 1 previous systemic regimen metastatic renal carcinoma History acute myocardial infarction within 6 month Clinically significant cardiovascular disease History stroke within 6 month Patients active brain metastasis Patients meningeal metastasis Women pregnant lactating Patients treat within 5 year invasive cancer Patients history evidence physical examination CNS disease Patients clinical history hemoptysis hematemesis Patients history deep vein thrombosis thromboembolic disease require full dose anticoagulation Patients major surgical procedure , open biopsy , significant traumatic injury within 28 day anticipate need major surgical procedure course study Patients pegtubes Gtubes Patients ineligible fine needle aspiration biopsy perform within seven day Patients proteinuria Patients nonhealing wound , ulcer , longbone fracture Patients history bleed diathesis coagulopathy History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month Patients receive experimental drug within 28 day start treatment History severe and/or uncontrolled medical disease History HIV infection Chronic treatment steroid immunosuppressive agent Patients impaired GI function compromise ability swallow absorb RAD001 Patients unwilling unable comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>kidney cancer</keyword>
	<keyword>bevacizumab</keyword>
</DOC>